Oncology (Williston Park, N.Y.)
[No authors listed]
PMID: 1531601
Oncology (Williston Park). 1992 Jan;6(1):142-3.
No abstract available.
Cite
The cost of developing new drugs. Oncology (Williston Park). 1992;6(1):142-3
(1992). The cost of developing new drugs. Oncology (Williston Park, N.Y.), 6(1), 142-3.
"The cost of developing new drugs." Oncology (Williston Park, N.Y.) vol. 6,1 (1992): 142-3.
The cost of developing new drugs. Oncology (Williston Park). 1992 Jan;6(1):142-3. PMID: 1531601.
Copy
Download .nbib
British journal of hospital medicine
Calvey TN.
PMID: 1591555
Br J Hosp Med. 1992 Apr 15-May 5;47(8):567-9.
No abstract available.
Cite
Calvey TN. Designing drugs. Br J Hosp Med. 1992;47(8):567-9
Calvey, T. N. (1992). Designing drugs. British journal of hospital medicine, 47(8), 567-9.
Calvey, T N. "Designing drugs." British journal of hospital medicine vol. 47,8 (1992): 567-9.
Calvey TN. Designing drugs. Br J Hosp Med. 1992 Apr 15-May 5;47(8):567-9. PMID: 1591555.
Copy
Download .nbib
Journal of medicinal chemistry
Hurley LH.
PMID: 2671370
J Med Chem. 1989 Sep;32(9):2027-33. doi: 10.1021/jm00129a001.
No abstract available.
Cite
Hurley LH. DNA and associated targets for drug design. J Med Chem. 1989;32(9):2027-33doi: 10.1021/jm00129a001.
Hurley, L. H. (1989). DNA and associated targets for drug design. Journal of medicinal chemistry, 32(9), 2027-33. https://doi.org/10.1021/jm00129a001
Hurley, L H. "DNA and associated targets for drug design." Journal of medicinal chemistry vol. 32,9 (1989): 2027-33. doi: https://doi.org/10.1021/jm00129a001
Hurley LH. DNA and associated targets for drug design. J Med Chem. 1989 Sep;32(9):2027-33. doi: 10.1021/jm00129a001. PMID: 2671370.
Copy
Download .nbib
Journal of computer-aided molecular design
Counts RW.
PMID: 2092085
J Comput Aided Mol Des. 1990 Dec;4(4):427-8. doi: 10.1007/BF00117407.
No abstract available.
Cite
Counts RW. Computation space. J Comput Aided Mol Des. 1990;4(4):427-8doi: 10.1007/BF00117407.
Counts, R. W. (1990). Computation space. Journal of computer-aided molecular design, 4(4), 427-8. https://doi.org/10.1007/BF00117407
Counts, R W. "Computation space." Journal of computer-aided molecular design vol. 4,4 (1990): 427-8. doi: https://doi.org/10.1007/BF00117407
Counts RW. Computation space. J Comput Aided Mol Des. 1990 Dec;4(4):427-8. doi: 10.1007/BF00117407. PMID: 2092085.
Copy
Download .nbib
Electrophoresis
Steiner S, Witzmann FA.
PMID: 10892720
Electrophoresis. 2000 Jun;21(11):2099-104. doi: 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N.
Advances in DNA sequencing and the near-term availability of whole genome sequences for several pharmaceutically relevant organisms promise to dramatically alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public...
Cite
Steiner S, Witzmann FA. Proteomics: applications and opportunities in preclinical drug development. Electrophoresis. 2000;21(11):2099-104doi: 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N.
Steiner, S., & Witzmann, F. A. (2000). Proteomics: applications and opportunities in preclinical drug development. Electrophoresis, 21(11), 2099-104. https://doi.org/10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N
Steiner, S, and Witzmann, F A. "Proteomics: applications and opportunities in preclinical drug development." Electrophoresis vol. 21,11 (2000): 2099-104. doi: https://doi.org/10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N
Steiner S, Witzmann FA. Proteomics: applications and opportunities in preclinical drug development. Electrophoresis. 2000 Jun;21(11):2099-104. doi: 10.1002/1522-2683(20000601)21:11<2099::AID-ELPS2099>3.0.CO;2-N. PMID: 10892720.
Copy
Download .nbib
BioTechniques
Dean PM, Zanders ED.
PMID: 11906004
Biotechniques. 2002 Mar;28-33.
The Human Genome Project has fueled the massive information-driven growth of genomics and proteomics and promises to deliver new insights into biology and medicine. Since proteins represent the majority of drug targets, these molecules are the focus of activity...
Cite
Dean PM, Zanders ED. The use of chemical design tools to transform proteomics data into drug candidates. Biotechniques. 2002;28-33
Dean, P. M., & Zanders, E. D. (2002). The use of chemical design tools to transform proteomics data into drug candidates. BioTechniques, 28-33.
Dean, Philip M, and Zanders, Edward D. "The use of chemical design tools to transform proteomics data into drug candidates." BioTechniques vol. (2002): 28-33.
Dean PM, Zanders ED. The use of chemical design tools to transform proteomics data into drug candidates. Biotechniques. 2002 Mar;28-33. PMID: 11906004.
Copy
Download .nbib
Yao xue xue bao = Acta pharmaceutica Sinica
Li WZ, Yun LH.
PMID: 12016878
Yao Xue Xue Bao. 1998 Sep;33(9):710-6.
No abstract available.
Cite
Li WZ, Yun LH. [Effective paradigms in drug discovery: integration of combinatorial chemistry with rational drug design]. Yao Xue Xue Bao. 1998;33(9):710-6
Li, W. Z., & Yun, L. H. (1998). [Effective paradigms in drug discovery: integration of combinatorial chemistry with rational drug design]. Yao xue xue bao = Acta pharmaceutica Sinica, 33(9), 710-6.
Li, W Z, and Yun, L H. "[Effective paradigms in drug discovery: integration of combinatorial chemistry with rational drug design]." Yao xue xue bao = Acta pharmaceutica Sinica vol. 33,9 (1998): 710-6.
Li WZ, Yun LH. [Effective paradigms in drug discovery: integration of combinatorial chemistry with rational drug design]. Yao Xue Xue Bao. 1998 Sep;33(9):710-6. Chinese. PMID: 12016878.
Copy
Download .nbib
Drug discovery today
Wess G.
PMID: 12047844
Drug Discov Today. 2002 May 15;7(10):533-5. doi: 10.1016/s1359-6446(02)02252-3.
No abstract available.
Cite
Wess G. How to escape the bottleneck of medicinal chemistry. Drug Discov Today. 2002;7(10):533-5doi: 10.1016/s1359-6446(02)02252-3.
Wess, G. (2002). How to escape the bottleneck of medicinal chemistry. Drug discovery today, 7(10), 533-5. https://doi.org/10.1016/s1359-6446(02)02252-3
Wess, Günther. "How to escape the bottleneck of medicinal chemistry." Drug discovery today vol. 7,10 (2002): 533-5. doi: https://doi.org/10.1016/s1359-6446(02)02252-3
Wess G. How to escape the bottleneck of medicinal chemistry. Drug Discov Today. 2002 May 15;7(10):533-5. doi: 10.1016/s1359-6446(02)02252-3. PMID: 12047844.
Copy
Download .nbib
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme
Kano S.
PMID: 10771653
Tanpakushitsu Kakusan Koso. 2000 Apr;45(6):928-34.
No abstract available.
Cite
Kano S. [The comparative analysis of alternatives for university industry relations]. Tanpakushitsu Kakusan Koso. 2000;45(6):928-34
Kano, S. (2000). [The comparative analysis of alternatives for university industry relations]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 45(6), 928-34.
Kano, S. "[The comparative analysis of alternatives for university industry relations]." Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme vol. 45,6 (2000): 928-34.
Kano S. [The comparative analysis of alternatives for university industry relations]. Tanpakushitsu Kakusan Koso. 2000 Apr;45(6):928-34. Japanese. PMID: 10771653.
Copy
Download .nbib
Drug discovery today
Dickins M, Modi S.
PMID: 12547029
Drug Discov Today. 2002 Jul 15;7(14):755-6. doi: 10.1016/s1359-6446(02)02357-7.
No abstract available.
Cite
Dickins M, Modi S. The importance of predictive ADME simulation. Drug Discov Today. 2002;7(14):755-6doi: 10.1016/s1359-6446(02)02357-7.
Dickins, M., & Modi, S. (2002). The importance of predictive ADME simulation. Drug discovery today, 7(14), 755-6. https://doi.org/10.1016/s1359-6446(02)02357-7
Dickins, Maurice, and Modi, Sandeep. "The importance of predictive ADME simulation." Drug discovery today vol. 7,14 (2002): 755-6. doi: https://doi.org/10.1016/s1359-6446(02)02357-7
Dickins M, Modi S. The importance of predictive ADME simulation. Drug Discov Today. 2002 Jul 15;7(14):755-6. doi: 10.1016/s1359-6446(02)02357-7. PMID: 12547029.
Copy
Download .nbib
Drug discovery today
Carr R, Jhoti H.
PMID: 11983569
Drug Discov Today. 2002 May 01;7(9):522-7. doi: 10.1016/s1359-6446(02)02245-6.
Conventional bioassay-based screening remains a mainstream approach for lead discovery. However, its limitations have meant that other, more biophysical methods, such as X-ray crystallography and NMR, are now being developed as lead discovery tools. These methods are particularly effective...
Cite
Carr R, Jhoti H. Structure-based screening of low-affinity compounds. Drug Discov Today. 2002;7(9):522-7doi: 10.1016/s1359-6446(02)02245-6.
Carr, R., & Jhoti, H. (2002). Structure-based screening of low-affinity compounds. Drug discovery today, 7(9), 522-7. https://doi.org/10.1016/s1359-6446(02)02245-6
Carr, Robin, and Jhoti, Harren. "Structure-based screening of low-affinity compounds." Drug discovery today vol. 7,9 (2002): 522-7. doi: https://doi.org/10.1016/s1359-6446(02)02245-6
Carr R, Jhoti H. Structure-based screening of low-affinity compounds. Drug Discov Today. 2002 May 01;7(9):522-7. doi: 10.1016/s1359-6446(02)02245-6. PMID: 11983569.
Copy
Download .nbib
Nature reviews. Drug discovery
[No authors listed]
PMID: 12755124
Nat Rev Drug Discov. 2003 May;2(5):335. doi: 10.1038/nrd1097.
No abstract available.
Cite
A call to arms for drug discoverers. Nat Rev Drug Discov. 2003;2(5):335doi: 10.1038/nrd1097.
(2003). A call to arms for drug discoverers. Nature reviews. Drug discovery, 2(5), 335. https://doi.org/10.1038/nrd1097
"A call to arms for drug discoverers." Nature reviews. Drug discovery vol. 2,5 (2003): 335. doi: https://doi.org/10.1038/nrd1097
A call to arms for drug discoverers. Nat Rev Drug Discov. 2003 May;2(5):335. doi: 10.1038/nrd1097. PMID: 12755124.
Copy
Download .nbib
